DrugPatentWatch Database Preview
Drugs in Development Information for PF-04958242
Email this page to a colleague
See Plans and PricingWhat is the development status for investigational drug PF-04958242?
PF-04958242 is an investigational drug.
There have been 14 clinical trials for PF-04958242.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Schizophrenia, Cognition Disorders, and Deafness. The leading clinical trial sponsors are Pfizer, Biogen, and Yale University.
There are thirty-eight US patents protecting this investigational drug and three hundred and fifty-one international patents.
Summary for PF-04958242
| US Patents | 38 |
| International Patents | 351 |
| US Patent Applications | 47 |
| WIPO Patent Applications | 16 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-11-15) |
| Vendors | 3 |
Recent Clinical Trials for PF-04958242
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Biogen | Phase 1 |
| A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen | Phase 2 |
| A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Pfizer | Phase 2 |
Clinical Trial Summary for PF-04958242
Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242
US Patents for PF-04958242
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-04958242 | Start Trial | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | Start Trial |
| PF-04958242 | Start Trial | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | Pfizer Inc. (New York, NY) | Start Trial |
| PF-04958242 | Start Trial | Imidazopyridazine compounds | Pfizer Inc. (New York, NY) | Start Trial |
| PF-04958242 | Start Trial | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides | Pfizer Inc. (New York, NY) | Start Trial |
| PF-04958242 | Start Trial | Pyrazolopyrimidine compounds | Pfizer Inc. (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-04958242
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-04958242 | Argentina | 099997 | 2034-04-10 | Start Trial |
| PF-04958242 | Australia | 2015245260 | 2034-04-10 | Start Trial |
| PF-04958242 | Canada | 2944971 | 2034-04-10 | Start Trial |
| PF-04958242 | Chile | 2016002510 | 2034-04-10 | Start Trial |
| PF-04958242 | China | 106459088 | 2034-04-10 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
